The Post-Finasteride Syndrome Foundation’s primary mission is to fund research on the characterization, underlying biologic mechanisms and treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS and providing support for patients suffering from the condition.
Adverse drug reaction reports worldwide
PFS research studies published
Known suicides worldwide
Doctors & researchers speaking out
Nations warning of PFS
Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.
An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use – insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.
—Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020
Even if the incidence of persistent sexual adverse events is 3% to 5%… approximately 900,000 to 1.5 million men would suffer persistent sexual and psychiatric adverse events.
[A]pproximately 30 million young men, worldwide, would be prescribed finasteride or dutasteride to treat male pattern hair loss. Even if the incidence of persistent sexual adverse events is 3% to 5%, which may be viewed as a small number, approximately 900,000 to 1.5 million men would suffer persistent sexual and psychiatric adverse events. By no means this would be considered a small number and should not be dismissed or ignored.
—Post-finasteride syndrome: a surmountable challenge for clinicians: Fertility and Sterility, January 2020
We wouldn’t recommend that any man take [finasteride], especially not young men.
We are certainly very cautious, because we see the side effects. We wouldn’t recommend that any man take [finasteride], especially not young men. The longer they take it, the greater the risk of experiencing persistent side effects, including after they’ve stopped.
—Do Anti-Baldness Remedies Make You Impotent? Puls, SRF-TV, May 7, 2018
FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks.
Finasteride inhibits Type II 5(alpha)-reductase, which metabolizes testosterone to the potent androgen 5(alpha)-dihydrotestosterone. FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks regarding growth, development and sexual function.
—FDA response to Merck & Co.’s citizen petition requesting that finasteride be added to the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: May 2000
SOMERSET, N.J., Jan. 5, 2016 – Reports of finasteride-induced Suicidal and Self-Injurious Behavior are up 33 percent in the World Health Organization Progamme for International Drug Monitoring’s database of adverse drug reactions (ADRs) for Q4 vs. Q3 2015. Within that category (itself a subcategory of Psychiatric Disorders), suicidal ideaton is up 47.2%; suicide attempts up […]
SOMERSET, N.J., Jan. 5, 2016 – Traffic to the PFS Foundation website rose 33.6 percent in 2015, compared to 2014, according to Google Analytics. Concurrently, users in 161 countries—or 82.5 percent of the world (as defined by the 195 nations recognized by the U.S. Department of State)—accessed information on the condition via PFSFoundation.org in 2015, […]
SOMERSET, N.J., Sept. 9, 2015 – The Post-Finasteride Syndrome Foundation is reminding PFS patients to report all persistent side effects to their respective national pharmacovigilance authorities for inclusion in the World Health Organization Progamme for International Drug Monitoring’s VigiBase database for adverse drug reactions (ADRs). Run by Uppsala Monitoring Centre (UMC), which provides scientific leadership […]
SOMERSET, N.J., Sept. 7, 2015 – Data from preclinical and clinical studies have provided substantial evidence that 5α-Reductase inhibitors (5α-RIs) such as finasteride and dutasteride cause loss or reduction of libido, increase the risk of erectile dysfunction and ejaculatory dysfunction, and may contribute to the onset of depression. These agents interfere with the biosynthesis and […]
SOMERSET, N.J., Aug. 26, 2015 – Twenty-five percent of men currently taking finasteride or dutasteride (brand names Proscar and Avodart) for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss are also at risk for adverse events elicited by […]